Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
Catherine G DeringtonJordana B CohenApril F MohantyTom H GreeneJames CookJian YingGuo WeiJennifer S HerrickVanessa W StevensBarbara E JonesLibo WangAlexander R ZheutlinAndrew Michael SouthThomas C HanffSteven M SmithRhonda M Cooper-DeHoffJordan B KingG Caleb AlexanderDan R BerlowitzFaraz S AhmadM Jason PenrodRachel HessMolly B ConroyJames C FangMichael A RubinSrinivasan BeddhuAlfred K CheungWeiming XianWilliam S WeintraubAdam P BressPublished in: PloS one (2021)
This observational analysis supports continued ARB or ACEI use for patients already using these medications before SARS-CoV-2 infection. The novel beneficial association observed among outpatients between users of ARBs vs. ACEIs on hospitalization or mortality should be confirmed with randomized trials.
Keyphrases
- angiotensin converting enzyme
- angiotensin ii
- vascular smooth muscle cells
- end stage renal disease
- coronavirus disease
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- risk factors
- respiratory syndrome coronavirus
- cardiovascular events
- type diabetes
- metabolic syndrome
- cross sectional
- patient reported outcomes
- weight loss
- drug induced
- glycemic control